-
br Cell cycle analysis br
2020-08-30
2.3. Cell cycle analysis After treatment with celastrol (0, 0.25, 0.5, and 1 μM) for 24 h, the 50-23-7 were collected and fixed with 75% ethanol (1 × 106/ml) at -20 °C overnight, washed with phosphate-buffered saline (PBS), and treated with RNase I, then stained with propidium iodide (BD Bioscie
-
br Minami D Takigawa N Takeda H Takata
2020-08-30
41. Minami D, Takigawa N, Takeda H, Takata M, Ochi N, Ichihara E, et al. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol Cancer Res 2013;11(2):140-8. 42. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations i
-
br Conflicts of interest br The authors declare
2020-08-28
Conflicts of interest The authors declare no competing interests. Availability of data and materials The data of patients used in this study are available from the corresponding author upon reasonable request. Consent for publication Not applicable. Ethics approval and consent to
-
br Note Arrow indicates screening guideline change in
2020-08-18
Note: Arrow indicates screening guideline change in 2009 for breast cancer. Lines were joinpoint regression lines. Among women aged 40−49 years: APC, annual percentage changes; J -, joinpoint regression line. which resulted in little change in the overall cancer inci-dence and stage distr
-
br Anxiety and depression HAD br The mean
2020-08-18
3.4. Anxiety and depression (HAD) The mean anxiety scores reported by women with cancer at the one-year and long-term assessment were 5.0 (SD 4.1) and 6.2 (SD 4.3), respectively. Corresponding figures for women without cancer at one-year and long-term were 4.2 (SD 3.7) and 4.5 (SD 4.3). The mea
-
br Estrone sulphate E S
2020-08-18
Estrone-sulphate (E1S) was determined using 300 μl of plasma sam-ples that were pre-processed by adding 650 μl of acetonitrile and 20 ng of the internal standard (d4-E1S). E1S was measured by Thermo Scien-tific TSQ Vantage system (Thermo Scientific, Breda, The Netherlands) equipped with a HESI-2 i
-
br Fig In vivo targeting ability and PTT e cacy
2020-08-18
Fig. 6. In vivo targeting ability and PTT efficacy of PMDIs. (A) In vivo behavior, fluorescence intensity and imaging of major tissues at 48 h post injection after MDA-MB-231 back tumor-bearing nude mice. (B) In vivo imaging of tumors treated with DINPs and PMDIs at 6 h post injection by confocal la
-
br Conclusion br This work
2020-08-18
4. Conclusion This work demonstrated the characterization and cytotoxicity of the biogenic MgONPs and Ag-MgONPs. The high throughput bio-materials characterization results revealed the successful fabrica-tion of the NPs. Particularly, the XPS and EDS results strongly evidenced the formation
-
br Inhibition of cytokines TNF a and interleukins
2020-08-18
2.5.3. Inhibition of cytokines (TNF-a and interleukins) TNF- a (Tumor necrosis factor alpha) which is produced in im-mune and tumor Ibrutinib plays a central role in inflammation, apoptosis, and cancer progression. Cell surface TNF-a can induce lysis in tumor cells or surrounding cells which i
-
br colorectal cancer cells in vitro
2020-08-18
colorectal cancer 1449-05-4 in vitro and in vivo. We first conducted MTT and clonal formation experiments to study the anti-proliferation effect of BA in vitro. The results showed that BA had cytotoxic and inhibitory effects on colorectal cancer cells. To further investigate the anti-proliferatio
-
br Study design br Two
2020-08-18
Study design Two ROs (JV and SD), well trained in delineation of OARs for HNC RT and familiar with the delineation guidelines [28,29], each delineated the 16 OARs on all 15 CT scans twice, using Eclipse (Var-ian Medical Systems, Palo Alto, CA), in 2 separate, uninterrupted sessions for each pat
-
br Table br Number of Barriers and
2020-08-18
Table 5 Number of Barriers and Facilitators Predicting Prior Screening (Never screened vs. Screened), Adjusted For Age Group (N = 338). Barriers: Facilitators: Table 6 Individual Barriers and Facilitators in Regards to Prior Screening (Never Screened vs. Prior Screener) (N = 330).
-
br Strengths and limitations of the study br
2020-08-18
5. Strengths and limitations of the study The results of this research can be generalized with caution to the Coelenterazine with the same criteria used by this study due to the con-secutive sampling method. In addition, since the study was descriptive and correlational, it was not possible to
-
br From the Department of Pathology College of Medicine Univ
2020-08-14
From the Department of Pathology,* College of Medicine, University of Illinois at Chicago, Chicago; and the Department of Urology,y Feinberg College of Medicine, Northwestern University, Chicago, Illinois Accepted for publication December 20, 2018. A subset of men with prostate cancer develo
-
br therapy or the only adjuvant therapy Furthermore given th
2020-08-14
therapy or the only adjuvant therapy? Furthermore, given that the addi-tion of RT did not yield an OS benefit for the group as a whole, the pa-tients for whom this treatment strategy may yield the greatest benefit would most likely have significant risk for LRR while a relatively low competing ris